The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .sub.1-adrenergic receptor (.sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .sub.1-adrenergic receptor (.sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

The present invention concerns a compound having the following formula (I): wherein: A is in particular N(R.sub.a)C(O)R, R.sub.a being H or a (C.sub.1-C.sub.6)alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: SO.sub.2N(R.sub.b), R.sub.b being H or a (C.sub.1-C.sub.6)alkyl group, N(R.sub.b)SO.sub.2, Rb being H or a (C.sub.1-C.sub.6)alkyl group, CONH, and NHCO, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

##STR00001##

The present invention concerns a compound having the following formula (I): wherein: A is in particular N(R.sub.a)C(O)R, R.sub.a being H or a (C.sub.1-C.sub.6)alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: SO.sub.2N(R.sub.b), R.sub.b being H or a (C.sub.1-C.sub.6)alkyl group, N(R.sub.b)SO.sub.2, Rb being H or a (C.sub.1-C.sub.6)alkyl group, CONH, and NHCO, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.

##STR00001##

The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.

The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.

Aqueous surfactant compositions comprising one or more alpha-sulfo fatty acid disalt (A) of general formula (I)
R.sup.1CH(SO.sub.3M.sup.1)COOM.sup.2(I), in which the radical R.sup.1 is a linear or branched alkyl or alkenyl radical having 6 to 18 carbon atoms and the radicals M.sup.1 and M.sup.2, independently of each other, are selected from H, Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine, one or more sulfosuccinate (B) of general formula (II)
R.sup.31OCOCH(SO.sub.3M.sup.16)CH.sub.2COOM.sup.17(II) wherein the radical R.sup.31 is a linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms or an alkoxylated linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms and the radicals M.sup.16 and M.sup.17, independently of each other, are selected from the group comprising H, Li, Na, K, Ca/2, Mg/2, ammonium and alkanolamines, and water. The compositions have good foaming ability, good skin compatibility, and a pleasant sensory feel to the foam, and are suitable for cosmetic products detergents, and cleaners.

Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

##STR00001##

This invention teaches a class of fluorinated benzensulfonamides of general structure I, as shown:

##STR00001## which are useful for inhibiting protein amyloid aggregation. The compounds taught can be used in pharmaceutical compositions in effective amounts to treat illnesses that result from protein amyloid aggregation.

This invention teaches a class of fluorinated benzensulfonamides of general structure I, as shown:

##STR00001## which are useful for inhibiting protein amyloid aggregation. The compounds taught can be used in pharmaceutical compositions in effective amounts to treat illnesses that result from protein amyloid aggregation.